AU2001246518A1 - A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease - Google Patents

A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease

Info

Publication number
AU2001246518A1
AU2001246518A1 AU2001246518A AU4651801A AU2001246518A1 AU 2001246518 A1 AU2001246518 A1 AU 2001246518A1 AU 2001246518 A AU2001246518 A AU 2001246518A AU 4651801 A AU4651801 A AU 4651801A AU 2001246518 A1 AU2001246518 A1 AU 2001246518A1
Authority
AU
Australia
Prior art keywords
disease
galantamine
alzheimer
targeting
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001246518A
Inventor
Wim Louis Julien Parys
Michael Pontecorvo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2001246518A1 publication Critical patent/AU2001246518A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001246518A 2000-04-03 2001-03-28 A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease Abandoned AU2001246518A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19426200P 2000-04-03 2000-04-03
US60194262 2000-04-03
PCT/EP2001/003551 WO2001074364A2 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease

Publications (1)

Publication Number Publication Date
AU2001246518A1 true AU2001246518A1 (en) 2001-10-15

Family

ID=22716910

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001246518A Abandoned AU2001246518A1 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease

Country Status (4)

Country Link
EP (1) EP1272190A2 (en)
AU (1) AU2001246518A1 (en)
CA (1) CA2310990A1 (en)
WO (1) WO2001074364A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
EP3297632A4 (en) * 2015-05-18 2019-01-16 Synaptec Development LLC GALANTAMINE CLEARANCE OF AMYLOIDß

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
JP5558648B2 (en) 1998-11-23 2014-07-23 デイビス、ボニー Administration formulation for acetylcholinesterase inhibitors

Also Published As

Publication number Publication date
CA2310990A1 (en) 2000-10-09
WO2001074364A3 (en) 2002-05-16
EP1272190A2 (en) 2003-01-08
WO2001074364A2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
AU2001273132A1 (en) Compounds to treat alzheimer's disease
AU2001233299A1 (en) Methods for treating alzheimer's disease
IL153214A0 (en) Compounds to treat alzheimer's disease
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
AU2001278084A1 (en) Model for alzheimer's disease and other neurodegenerative diseases
AU1407399A (en) Treatment for alzheimer's disease
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2001236592A1 (en) Methods for diagnosis of alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
AU2001248760A1 (en) Preventives/remedies for alzheimer's disease
AU1405899A (en) Treatment for alzheimer's disease
GB0011410D0 (en) Therapeutic combination for treating Alzheimer's disease
AU2002312667A1 (en) Individualization of therapy with alzheimer's disease agents
IL152061A0 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
GB0011408D0 (en) Therapeutic combination for treating Alzheimer's Disease
AU2001246518A1 (en) A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU2001267826A1 (en) Remedies for alzheimer's disease
AU2002364885A1 (en) Alzheimer's disease model
AU2001258569A1 (en) Alzheimer's disease assay
AU2002316622A1 (en) Aminediols for the treatment of alzheimer's disease
AU2002320537A1 (en) Diaminediols for the treatment of alzheimer's disease